Summary of Zhongke Information Conference Call Company Overview - **Company**: Zhongke Information - **Industry**: Brain-Computer Interface (BCI) and Medical Robotics Key Points Industry and Market Potential - The market potential for implanted brain-machine technology in anesthesia robots is estimated to be between **12 billion to 20 billion RMB** (approximately **$1.8 billion to $3 billion**) with a projected **30% penetration rate** [2][4] - The company plans to expand into rehabilitation and pain management sectors, currently conducting trials at the **Wan'an Rehabilitation Hospital** in Tianfu New District [2][4] Product Development and Clinical Trials - Zhongke Information's anesthesia robot has completed **15 clinical trials** successfully, with plans to complete **200 trials** to obtain a Class III medical device certification from the state [2][5] - The company expects to finish clinical trials and submit for certification by the end of this year, aiming for revenue generation by **the second half of 2027** [2][5] Technological Collaboration and Advancements - Collaboration with the **Suzhou Institute of Nano-Tech and Nano-Bionics** has improved the accuracy of EEG signal collection and decoding [3] - Despite being behind **Neuralink** in technology, Zhongke Information is leading in medical rehabilitation applications domestically [3] Revenue Model and Pricing - The expected price for each anesthesia robot is around **1 million RMB** (approximately **$150,000**) [5][7] - Currently, the company employs a unified pricing model for the anesthesia robot, with no established independent pricing standards for its use in rehabilitation hospitals [5][7] Future Directions and Strategic Plans - The company is optimistic about its future, especially with the large-scale production plans of **Neuralink** and the inclusion of brain-machine interfaces in the national **14th Five-Year Plan** [6] - Zhongke Information aims to leverage its advantages as a national technology team and integrate resources from the Chinese Academy of Sciences to achieve breakthroughs in practical applications of brain-like intelligent technology [6] Insurance and Reimbursement Considerations - There is currently no clear indication whether the anesthesia robot will be included in health insurance coverage, and the company is monitoring policy developments closely [7] Additional Important Information - All domestic brain-machine interface products are still in clinical trial phases, with no products having received formal certification yet, indicating that full commercialization will take time [2][4]

（文章来源：证券日报） 证券日报网讯 1月5日，中科信息发布公告称，公司于近日收到全资子公司成都中科信息技术有限责任 公司（简称"成都中科"）的通知，因经营发展的需要，成都中科对其经营范围进行了变更，并按照国家 现行的表述规范对公司经营范围表述进行了调整。目前已完成工商变更登记手续，并取得了四川天府新 区智慧城市运行局换发的《营业执照》，本次变更仅涉及经营范围变更，其他事项不变。 ...

证券代码：300678 证券简称：中科信息 公告编号：2026-001 中科院成都信息技术股份有限公司 关于全资子公司变更经营范围并完成工商登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 4.住 所：四川天府新区兴隆街道科智路 1369 号 5.法定代表人：史志明 6.注册资本：6000 万人民币 7.成立日期：2015 年 12 月 18 日 8.经营范围：一般项目：技术服务、技术开发、技术咨询、技术交 流、技术转让、技术推广；软件开发；软件外包服务；数据处理和存储 1 / 2 中科院成都信息技术股份有限公司（以下简称"公司"）于近日收 到全资子公司成都中科信息技术有限责任公司（以下简称"成都中科"） 的通知，因经营发展的需要，成都中科对其经营范围进行了变更，并按 照国家现行的表述规范对公司经营范围表述进行了调整。 目前已完成工商变更登记手续，并取得了四川天府新区智慧城市运 行局换发的《营业执照》，本次变更仅涉及经营范围变更，其他事项不 变。具体情况如下： 一、变更后的营业执照信息 1.公司统一社会信用代码：91510100MA61T0349K ...

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

每经AI快讯，1月5日，脑机接口概念盘中持续扩大涨幅，博拓生物、航天长峰（600855）封涨停，此 前倍益康、三博脑科（301293）、翔宇医疗、伟思医疗、诚益通（300430）等近20股涨停，冠昊生物 （300238）、狄耐克（300884）、中科信息（300678）、汉威科技（300007）、道氏技术（300409）等 多股涨超10%。 ...

Group 1 - The company emphasizes its commitment to information and cybersecurity issues, indicating a proactive approach to these challenges [2] - The products and solutions offered by the company across various industries incorporate effective offensive and defensive technologies, as well as emergency mechanisms [2]

Core Viewpoint - Zhongke Information's stock price has shown volatility, with a year-to-date decline of 16.69% but a recent increase of 2.93% over the last five trading days, indicating potential recovery signals in the market [1]. Group 1: Stock Performance - As of December 24, Zhongke Information's stock price is 30.26 CNY per share, with a market capitalization of 8.969 billion CNY [1]. - The stock has experienced a trading volume of 78.7984 million CNY, with a turnover rate of 0.90% [1]. - The company has seen a net inflow of main funds amounting to 1.2402 million CNY, with large orders accounting for 16.25% of total purchases [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhongke Information reported a revenue of 194 million CNY, reflecting a year-on-year decrease of 11.22% [2]. - The net profit attributable to shareholders for the same period was 4.5133 million CNY, down 27.07% year-on-year [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhongke Information is 48,900, a decrease of 16.28% from the previous period [2]. - The average number of tradable shares per shareholder has increased by 19.34% to 5,945 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.6567 million shares to 2.9402 million shares [3].

格隆汇12月23日丨中科信息(300678.SZ)在投资者互动平台表示，公司未开展手机相关业务。 ...

Capital Operations - Shen Cheng Jiao plans to raise no more than 1.8 billion yuan through a private placement for the research and large-scale application of low-altitude and autonomous driving intelligent transportation equipment and related projects [2] - Ding Gu Ji Chuang's invested company Hang Ju Technology has developed the WS series flexible reusable thermal protection materials, which have been applied to the Blue Arrow Aerospace Zhuque-3 rocket body [2] - Zhen You Technology has ongoing ground core network development projects in both high-orbit and low-orbit satellite communication fields [2] Investment and Operations - Zhongjin Company plans a stock swap merger with Dongxing Securities and Xinda Securities, with stock trading resuming on December 18 [1] - Beiqi Blue Valley aims to continue developing L3 models in the mid-to-high-end brand segment, with some L3 model products currently in the development stage [1] - Xingmin Zhitong's communication domain controller is currently being used in L3 and L4 autonomous vehicles, including Robotaxi and unmanned logistics vehicles [1] Contracts and Collaborations - Pudong Construction's subsidiary recently won contracts totaling 1.649 billion yuan [1] - China Duty Free Group's wholly-owned subsidiary signed a contract for the transfer of duty-free store project operating rights, planning to invest 102 million yuan to establish a joint venture with Shanghai Airport [1] - Shanghai Airport signed a contract with Dufry and China Duty Free Group for the transfer of duty-free store project operating rights, with Dayang Shanghai not renewing the contract [1] - China CRRC and its subsidiaries recently signed contracts totaling 53.31 billion yuan, with wind power and energy storage equipment sales contracts amounting to approximately 16.65 billion yuan [1] Performance - China Nuclear Construction reported a cumulative operating income of 92.03 billion yuan by November 2025 [4] Share Buybacks - Shibao Testing's executives plan to increase their holdings of company shares by 8 million to 12 million yuan [4]

Group 1 - The company has successfully completed over ten clinical trials for its intelligent anesthesia robot and aims to shorten the process through a "multi-center" layout, targeting certification for Class III medical devices by the end of 2028 [1] - The company plans to develop a comprehensive smart hospital solution centered around products such as the intelligent anesthesia robot and tumor adaptive radiotherapy platform for sales [1]